In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Year

    Select Year(s)

  • Session Type

    Select Session Type(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic

Sponsored content

Presentations below are part of sessions sponsored by Novartis Pharma AG

48 results for your search

Audience Q&A and panel discussion.

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : W Koenig (Munich,DE), P Libby (Boston,US), P M Ridker (Boston,US), J H Cornel (Alkmaar,NL)
  • Sponsored by Novartis Pharma AG

Case 2: My HF patient post-hospitalization is easy to manage!

Congress : Heart Failure 2018

  • Session : Heart failure case debates with the experts
  • Speaker : C S P Lam (Singapore,SG), J G F Cleland (Glasgow,GB)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Case1: my stable Heart Failure with reduced Ejection Fraction (HFrEF) patient: I should start an ARNI immediately!

Congress : Heart Failure 2018

  • Session : Heart failure case debates with the experts
  • Speaker : M Packer (Dallas,US), S D Anker (Berlin,DE)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Conclusion - Heart Failure (HF) case debates with the experts.

Congress : Heart Failure 2018

  • Session : Heart failure case debates with the experts
  • Speaker : LH Lund (Stockholm,SE), S D Anker (Berlin,DE)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Dilemmas in heart failure management: what do the experts say?

Congress : ESC Congress 2018

  • Session : Dilemmas in heart failure management: what do the experts say?
  • Speaker : C S P Lam (Singapore,SG), B Pieske (Berlin,DE), S Solomon (Boston,US), F Ruschitzka (Zurich,CH), M Jessup (Hingham,US)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Emerging evidence-based approaches to reduce residual atherosclerotic risk - ask the experts.

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk - Ask the experts
  • Speaker : P M Ridker (Boston,US), A Catapano (Milan,IT)
  • Sponsored by Novartis Pharma AG

Examining heart failure cases with the experts: challenges faced.

Congress : Heart Failure 2018

  • Session : Examining heart failure cases with the experts: challenges faced
  • Speaker : C S P Lam (Singapore,SG), M Packer (Dallas,US), J G F Cleland (Glasgow,GB)
  • Sponsored by Novartis

Hospital admission for heart failure: an opportunity to optimize heart failure therapy?

Congress : ESC Congress 2018

  • Session : Seize the moment to optimize treatment for each patient with heart failure: why, when, and how
  • Speaker : R Wachter (Leipzig,DE)
  • Sponsored by Novartis Pharma AG

Identification of residual inflammatory cardiovascular risk.

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : J H Cornel (Alkmaar,NL)
  • Sponsored by Novartis Pharma AG

Inflammation in atherosclerosis: time for translation?

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : P Libby (Boston,US)
  • Sponsored by Novartis Pharma AG

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are